Philippe Colson to Betacoronavirus
This is a "connection" page, showing publications Philippe Colson has written about Betacoronavirus.
Connection Strength
0.233
-
Children account for a small proportion of diagnoses of SARS-CoV-2 infection and do not exhibit greater viral loads than adults. Eur J Clin Microbiol Infect Dis. 2020 Oct; 39(10):1983-1987.
Score: 0.038
-
Ultrarapid diagnosis, microscope imaging, genome sequencing, and culture isolation of SARS-CoV-2. Eur J Clin Microbiol Infect Dis. 2020 Aug; 39(8):1601-1603.
Score: 0.037
-
Letter to the editor: Plenty of coronaviruses but no SARS-CoV-2. Euro Surveill. 2020 02; 25(8).
Score: 0.037
-
Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis. Travel Med Infect Dis. 2020 Jul - Aug; 36:101791.
Score: 0.009
-
Comparison of mortality associated with respiratory viral infections between December 2019 and March 2020 with that of the previous year in Southeastern France. Int J Infect Dis. 2020 Jul; 96:154-156.
Score: 0.009
-
Child with liver transplant recovers from COVID-19 infection. A case report. Arch Pediatr. 2020 Jul; 27(5):275-276.
Score: 0.009
-
Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France. Travel Med Infect Dis. 2020 May - Jun; 35:101738.
Score: 0.009
-
Viral RNA load as determined by cell culture as a management tool for discharge of SARS-CoV-2 patients from infectious disease wards. Eur J Clin Microbiol Infect Dis. 2020 Jun; 39(6):1059-1061.
Score: 0.009
-
In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect. Microb Pathog. 2020 Aug; 145:104228.
Score: 0.009
-
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020 Jul; 56(1):105949.
Score: 0.009
-
Rapid viral diagnosis and ambulatory management of suspected COVID-19 cases presenting at the infectious diseases referral hospital in Marseille, France, - January 31st to March 1st, 2020: A respiratory virus snapshot. Travel Med Infect Dis. 2020 Jul - Aug; 36:101632.
Score: 0.009
-
SARS-CoV-2: fear versus data. Int J Antimicrob Agents. 2020 May; 55(5):105947.
Score: 0.009
-
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrob Agents. 2020 May; 55(5):105938.
Score: 0.009
-
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents. 2020 04; 55(4):105932.
Score: 0.009
-
Chloroquine for the 2019 novel coronavirus SARS-CoV-2. Int J Antimicrob Agents. 2020 03; 55(3):105923.
Score: 0.009
-
Does spitting in public play a role in transmitting SARS-CoV-2? Travel Med Infect Dis. 2020 Jul - Aug; 36:101759.
Score: 0.002
-
Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study. Travel Med Infect Dis. 2020 Mar - Apr; 34:101663.
Score: 0.002
-
Testing the repatriated for SARS-Cov2: Should laboratory-based quarantine replace traditional quarantine? Travel Med Infect Dis. 2020 Mar - Apr; 34:101624.
Score: 0.002
-
Teicoplanin: an alternative drug for the treatment of COVID-19? Int J Antimicrob Agents. 2020 Apr; 55(4):105944.
Score: 0.002